Psoriasis in Biological Technology
Navigation Links
Psoriasis in Biological Technology
... syndicated report TreatmentTrends (R) : psoriasis , the fourth annual survey of U.S. ... highlights shifting trends in the management of psoriasis and psoriatic arthritis. This comprehensive ... use of biologic agents.
The vast majority of psoriasis patients across all disease severity categories ...
... with inflamed, scaly, red patches of skin psoriasis and psoriasis nail involvement. Symptoms may include ... feet, lower back and neck are commonly affected. psoriasis affects an estimated two to three percent of the ...
... field its fourth annual TreatmentTrends(TM): psoriasis survey on April 13th with a special section ... by BioTrends, ChartTrends(TM): Biologics in psoriasis , is a report that is based on actual patient ... According to last year's TreatmentTrends(TM): psoriasis report, market share for Raptiva had steadily ...
... campaign designed to help people with plaque psoriasis get more information about managing their disease ... working together to encourage people with plaque psoriasis to visit a dermatologist and take the first step ... people who have moderate to severe plaque psoriasis but who try not to allow the condition to inhibit ...
... is for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a ... adults living with moderate-to-severe plaque psoriasis a new therapy which has the potential to make a ... in the treatment of moderate-to-severe plaque psoriasis were evaluated.(4,5) Two-thirds or more of ...
... in physical function and arthritis and psoriasis components of the disease. These findings were ... than 3 percent Body Surface Area (BSA) psoriasis skin involvement at baseline were evaluated for ... and enthesitis, as measured by the Nail psoriasis Severity Index (NAPSI) and the psoriatic ...
... with inflamed, scaly, red patches of skin psoriasis and psoriasis nail involvement. Symptoms may include stiffness ... feet, lower back and neck are commonly affected. psoriasis affects an estimated two to three percent of the ...
... treatment of moderate to severe plaque psoriasis. psoriasis will be the fifth disease indication for HUMIRA. psoriasis is a non-contagious, chronic autoimmune disease ... known as plaques, which may crack and bleed. But psoriasis is more than painful skin lesions; data also ...
... official site, which will be named at a later date include NEUROSKIN(R) psoriasis Relief, NEUROSKIN(R)Acne Treatment, NEUROSKIN(R) Itch Relief and ... relieve and treat the symptoms of common skin ailments, including: eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin(R) ...
... are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin(r) line of skin care products through mass, food and drug channels in the ...
... are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin(r) line of skin care products through mass, food and drug channels in the ...
... agent that works by inhibiting DNA replication. Nitrogen mustard has also demonstrated activity in other T-cell proliferating diseases such as psoriasis and alopecia areata and has a rich history of use in dermatology dating back to the 1950s. To date, topical nitrogen mustard has only been available ...
... medical, corrective and aesthetic solutions to treat a range of dermatological conditions including: acne, rosacea, fungal nail infections, psoriasis & other steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence. Galderma has research and ...
... (SLE) and a phase 1b study in patients with active dermatomyositis and polymyositis. The company has also conducted clinical trials in psoriasis with MEDI-545. -- CAM-3001 - CAM-3001 is a MAb with potential to help patients with rheumatoid arthritis. The antibody targets the alpha ...
... VBL has developed a new family of anti-inflammatory drugs for chronic inflammatory diseases, such as Rheumatoid Arthritis, Multiple Sclerosis, psoriasis and Inflammatory Bowel Disease. VBL has also developed the Vascular Targeting System (VTSTM), a new platform technology targeting the formation of ...
... we intend to initiate clinical development for the treatment of rheumatoid arthritis in early 2009; and our JAK3 program for the topical treatment of psoriasis which we expect to enter preclinical development in 2009. Discovery research remains a core strength of Pharmacopeia and will be increasingly focused ...
... in 2008: -- Already in 2008, the company has introduced two new indications for HUMIRA(R) (adalimumab) -- moderate to severe plaque psoriasis and moderate to severely active polyarticular juvenile idiopathic arthritis, both of which received U.S. Food and Drug Administration ...
... with inflamed, scaly, red patches of skin psoriasis and psoriasis nail involvement. Symptoms may include ... feet, lower back and neck are commonly affected. psoriasis affects an estimated two to three percent of the ...
... field its fourth annual TreatmentTrends(TM): psoriasis survey on April 13th with a special section ... by BioTrends, ChartTrends(TM): Biologics in psoriasis , is a report that is based on actual patient ... According to last year's TreatmentTrends(TM): psoriasis report, market share for Raptiva had steadily ...
... campaign designed to help people with plaque psoriasis get more information about managing their disease ... working together to encourage people with plaque psoriasis to visit a dermatologist and take the first step ... people who have moderate to severe plaque psoriasis but who try not to allow the condition to inhibit ...
... is for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a ... adults living with moderate-to-severe plaque psoriasis a new therapy which has the potential to make a ... in the treatment of moderate-to-severe plaque psoriasis were evaluated.(4,5) Two-thirds or more of ...
... in physical function and arthritis and psoriasis components of the disease. These findings were ... than 3 percent Body Surface Area (BSA) psoriasis skin involvement at baseline were evaluated for ... and enthesitis, as measured by the Nail psoriasis Severity Index (NAPSI) and the psoriatic ...
Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
... its third annual TreatmentTrends (TM): psoriasis publication, providing insight into the ... in their use of biologics for the treatment of psoriasis in the past year, particularly in patients with ... While the use of oral agents to treat psoriasis increases with disease severity, less ...... with inflamed, scaly, red patches of skin psoriasis and psoriasis nail involvement. Symptoms may include stiffness ... feet, lower back and neck are commonly affected. psoriasis affects an estimated two to three percent of the ...
NeoStrata(R) Announces the Launch of PSORENT(TM) Psoriasis Topical Treatment
... distillate), which has proven efficacy against psoriasis symptoms, in a novel, aesthetically advanced ... physicians will be able to offer patients a novel psoriasis treatment that reduces the unpleasant aspects ... first-line therapy for the vast majority of psoriasis patients." PSORENT is an aesthetically ...Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
... percent reduction in psoriasis as measured by the psoriasis Area and Severity Index (PASI 75). Acceptance of ... past Saturday, February 2. About Psoriasis psoriasis is a chronic, immune-mediated disease, which ... from debilitating immune disorders. 1. National psoriasis Foundation. About Psoriasis: ...Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
... is an established target for drug development in psoriasis and other autoimmune diseases. The effectiveness ... a planned Phase 2 clinical trial for plaque psoriasis beginning mid-2008, pending approval from the ... in the fourth quarter of 2008. We expect this psoriasis program will help to expand our product portfolio ...... treatment of moderate to severe plaque psoriasis. psoriasis will be the fifth disease indication for HUMIRA. psoriasis is a non-contagious, chronic autoimmune disease ... known as plaques, which may crack and bleed. But psoriasis is more than painful skin lesions; data also ...
Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
... biologics earlier in the course of treatment for psoriasis and psoriatic arthritis. According to the new Physician & Payer Forum report entitled psoriasis and Psoriatic Arthritis: The Expanding Biologics ... tried an average of 5.8 therapies for moderate psoriasis before turning to biologics. By mid-2008 they ...... official site, which will be named at a later date include NEUROSKIN(R) psoriasis Relief, NEUROSKIN(R)Acne Treatment, NEUROSKIN(R) Itch Relief and ... relieve and treat the symptoms of common skin ailments, including: eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin(R) ...
BioCis Pharma Starts Phase IIa Trial in Psoriasis
... expect to get results from both studies by third quarter of 2009." psoriasis is an immune-mediated chronic inflammatory disease characterized by local ... about 2 to 3 per cent of the general population in the Western countries. psoriasis may significantly impair the life quality of the affected subjects, and it ...FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
... under review by the European Medicines Agency (EMEA). About Psoriasis psoriasis is a chronic, immune-mediated disease, which results from ... people in the United States and 10 million Europeans are living with psoriasis and nearly one-quarter of those people have cases that are considered ...BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
... commercialization including forodesine HCl in oncology, BCX-4208 in psoriasis and peramivir in seasonal and life-threatening influenza. BioCryst is ... (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization ...William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
... commercialization including forodesine HCl in oncology, BCX-4208 in psoriasis and peramivir in seasonal and life-threatening influenza. BioCryst is ... (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization ...BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
... commercialization including forodesine HCl in oncology, BCX-4208 in psoriasis and peramivir in seasonal and life-threatening influenza. BioCryst is ... (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization ...Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
... "There are impressive new options for the treatment of aging skin, acne, psoriasis and a host of other conditions -- including bio-engineered collagen, ... for the development of new agents. Biologics are expected to dominate the psoriasis market with a 70% market share by 2011, due to the introduction of several ...Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
... ustekinumab will become the clinical gold standard for psoriasis by 2011. Ustekinumab will achieve gold standard status because of its ... is the attribute that most influences their prescribing decisions in psoriasis and clinical data shows that ustekinumab has advantages over sales-leading ...REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
... of adults with chronic, severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies ... is also approved in the EU for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or have a contraindication to, or are ...R-Tech Ueno Notifies R&D Items
... an unconventional action, VAP-1* inhibition. We intend to develop this compound as a drug indicated for atopic dermatitis, contact dermatitis and psoriasis vulgaris in the dermatological field, and diabetic neuropathy in the neurological field. We plan to report on the development status of each ...... are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin(r) line of skin care products through mass, food and drug channels in the ...
... are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin(r) line of skin care products through mass, food and drug channels in the ...
... agent that works by inhibiting DNA replication. Nitrogen mustard has also demonstrated activity in other T-cell proliferating diseases such as psoriasis and alopecia areata and has a rich history of use in dermatology dating back to the 1950s. To date, topical nitrogen mustard has only been available ...
... medical, corrective and aesthetic solutions to treat a range of dermatological conditions including: acne, rosacea, fungal nail infections, psoriasis & other steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence. Galderma has research and ...
Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
... future collaboration partner for R788 to jointly evaluate this indication and decide how to proceed. R348 Moving forward, Rigel plans to focus on psoriasis and possible topical applications with its Jak3 inhibitor, R348, and to do so with a collaboration partner. Rigel will move forward with another ...BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
... meeting. -- BioCryst reported top-line results from the completed Phase 2a trial of BCX-4208 in subjects with moderate to severe plaque psoriasis were consistent with interim findings. BCX-4208, a potent, rationally designed, orally available purine nucleoside phosphorylase ...... (SLE) and a phase 1b study in patients with active dermatomyositis and polymyositis. The company has also conducted clinical trials in psoriasis with MEDI-545. -- CAM-3001 - CAM-3001 is a MAb with potential to help patients with rheumatoid arthritis. The antibody targets the alpha ...
Merck Serono Named as a Top Employer by Science Magazine
... infertility (Gonal-f(R)), endocrine and cardiometabolic disorders (Glucophage(R), Concor(R), Euthyrox(R), Saizen(R), Serostim(R)), as well as psoriasis (Raptiva(R)). With an annual R&D expenditure of around EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic ...BioCryst to Present at the JMP Healthcare Focus Conference
... that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees ...Kuvan Receives Positive Opinion From CHMP for European Approval
... infertility (Gonal-f(R)), endocrine and cardiometabolic disorders (Glucophage(R), Concor(R), Euthyrox(R), Saizen(R), Serostim(R)), as well as psoriasis (Raptiva(R)). With an annual R&D expenditure of around euro 1bn, Merck Serono is committed to growing its business in specialist-focused ...BioCryst to Present at UBS 2008 Global Life Sciences Conference
... that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees ...GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
... such as PI3Kg and d, Zap-70, Jak3 and mTOR, as potential oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis and asthma. In addition to the GSK collaboration, Cellzome has an alliance with Johnson & Johnson focused on the discovery of novel medicines for ...... VBL has developed a new family of anti-inflammatory drugs for chronic inflammatory diseases, such as Rheumatoid Arthritis, Multiple Sclerosis, psoriasis and Inflammatory Bowel Disease. VBL has also developed the Vascular Targeting System (VTSTM), a new platform technology targeting the formation of ...
... we intend to initiate clinical development for the treatment of rheumatoid arthritis in early 2009; and our JAK3 program for the topical treatment of psoriasis which we expect to enter preclinical development in 2009. Discovery research remains a core strength of Pharmacopeia and will be increasingly focused ...
... in 2008: -- Already in 2008, the company has introduced two new indications for HUMIRA(R) (adalimumab) -- moderate to severe plaque psoriasis and moderate to severely active polyarticular juvenile idiopathic arthritis, both of which received U.S. Food and Drug Administration ...
Galderma Completes Acquisition of CollaGenex
... health of skin with an extensive line of products that treat a range of dermatological conditions including: acne, rosacea, fungal nail infections, psoriasis & steroid-responsive dermatoses, pigmentary disorders, medical solutions for skin senescence and skin cancers. With a research and development center ...BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
... that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees ...Other ContentsingestioningestioningestioningestioningestioningestionaddictionaddictionaddictionaddictionaddictionaddictiondrydrydrydrydrydrydrydrydryduodenalduodenaldyesdyesdyesdyesdyesdyesdysarthriadyspneadyspneadyspneadyslexiadyslexiaOther TagsLDFEmboEmboEmboDopDopDopDopDopDopDopOther Tagsmisuse 2misuse 3misuse 4documented 2documented 3documented 4documented 5documented 6documented 7documented 8documented 9documented 10ayurveda 2propose 2propose 3propose 4
(Date:12/2/2009)...cap is good for you, at least if you are a mammal ...eering in Oncology Center have shown that in healt...lds the cell,s nucleus, its genetic storehouse, in...nce on cell and nuclear shape, the researchers say...nt of diseases such as cancer, muscular dystrophy ...
(Date:12/2/2009)...., Dec. 2 DigitalPersona, Inc., a ...solutions, today announced an agreement with IBM t...ic fingerprint technology on IBM SurePOS 500 retai... offering allows point-of-sale applications to mor...ic transactions can be linked to the individuals w...
(Date:12/2/2009)... Commonly prescribed beta 2 adrenergic agonist dr...as well as pre-term labor may increase the inciden...logy, cognitive problems and poor school performan...lished in the December 2009 issue of the American...drenergic agonist drugs as a class are widely used...
Breaking Biology News(10 mins):A cell's 'cap' of bundled fibers could yield clues to disease 2DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2Treatments for asthma and pre-term labor may increase risk of autism in developing fetus 2The ends of mRNAs may prevent the beginnings of cancer 9638 1The ends of mRNAs may prevent the beginnings of cancer 9638 2Disrupting a destructive duo 3A U of T Mississauga researchers inhibit cancer proteins 9634 1Disrupting a destructive duo 3A U of T Mississauga researchers inhibit cancer proteins 9634 2Nostrils Compete to Relay Key Fragrance 54963 1Nostrils Compete to Relay Key Fragrance 54963 2(Date:12/2/2009)... -- Reportlinker.com announces that a new market r..., Antibiotic Resistance and Antibiotic Technologi....com/p0166825/Antibiotic-Resistance-and-Antibiotic...n in-depth review of the global market for antibio... Offer an analysis of antibiotics resistance from ...
(Date:12/2/2009)...e/ -- The Washington Post reported that Cyber Mond...rics, a marketing optimization company, internet s... Cyber Monday 2008. ,, Contrast those statistic...today "Cyber Monday website traffic rose 76% and C...y Amorosino, COO of Bella Sante. ,, Why is Be...
(Date:12/2/2009)...ounter recent increases in longevity , ,... health of the U.S. population has improved over t... quit smoking in droves, but a new study suggests ...obesity rates among Americans don,t level off or d...esity continue unchanged, the average life expecta...
(Date:12/2/2009)..., researchers say , , WEDNESDAY, Dec. 2 ...yme replacement therapy can make a major differenc...e illness that affects the kidneys, heart and brai...ck of an enzyme that helps metabolic pathways func...he risk for a stroke, heart attack and kidney dise...
(Date:12/2/2009)...swire/ -- By now, most people have heard of the e-...grow in popularity. And, the latest product on the...- the new single piece PremiumOne(TM) disposable e...f $14.99. ,, "This new product makes it possibl...price, before making a bigger investment in a smok...
Breaking Medicine News(10 mins):Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 2Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 3Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 4Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 5Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 6Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 7Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 8Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 9Health News:The Washington Post Reported That Cyber Monday Website Traffic Rises 8%. Boston's Bella Sante Day Spas Cyber Monday Website Traffic Rises 76%. 2Health News:The Washington Post Reported That Cyber Monday Website Traffic Rises 8%. Boston's Bella Sante Day Spas Cyber Monday Website Traffic Rises 76%. 3Health News:Health Gains From Lowered Smoking Rates in Jeopardy 2Health News:Health Gains From Lowered Smoking Rates in Jeopardy 3Health News:A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product 2[0] Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets[0] The Washington Post Reported That Cyber Monday Website Traffic Rises 8%. Boston's Bella Sante Day Spas Cyber Monday Website Traffic Rises 76%.[0] Health Gains From Lowered Smoking Rates in Jeopardy[0] Enzyme Replacement May Help in Fabry Disease[2] A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |